- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00967993
Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
A 6-Week Feasibility Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Ashkelon, Israel, 78306
- Barzilai Medical Center Ben-Gurion University
-
Jerusalem, Israel, 91120
- Hadassah University Hospital-Ein Kerem
-
Zerifin, Israel, 70300
- Assaf Haraofeh Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Males and non-pregnant, non-lactating females
- Age > 18 years
- On thrice weekly hemodialysis for at least the previous three months prior to screening
- Serum phosphorus levels ≥ 2.5 mg/dL and < 8.5 mg/dL at Screening Visit (Visit 0)
- Serum phosphorus levels > 5.5 mg/dL at Study Drug Initiation Visit (Visit 3)
- Taking 3 to 18 tablets/capsules/day of calcium acetate calcium carbonate, lanthanum carbonate, sevelamer (hydrochloride or carbonate), or any combination of these agents as reported by the patient at screening
- Serum ferritin <1000micrograms/L and Transferrin Saturation (TSAT) <50%
- Willing to be discontinued from current phosphate binder(s) and initiated on KRX-0502 (ferric citrate)
- Willing and able to give informed consent
Exclusion Criteria:
- Parathyroidectomy within six months prior to Screening Visit (Visit 0)
- Actively symptomatic gastrointestinal bleeding and inflammatory bowel disease
- Serum phosphorus levels >10.0 mg/dL documented in the three monthly laboratories (done routinely in the dialysis unit) in the three months prior to the Screening Visit (Visit 0)
- History of multiple drug allergies
- History of malignancy in the last five years (treated cervical or skin cancer may be permitted if approved by Keryx)
- Previous intolerance to oral ferric citrate
- Absolute requirement for oral iron therapy
- Absolute requirement for Vitamin C (multivitamins [Centrum, Nephrocaps, Renaphro, etc.] allowed)
- Absolute requirement for calcium, magnesium, or aluminum containing drugs with meals
- Psychiatric disorder that interferes with the patient's ability to comply with the study protocol
- Inability to tolerate oral drug intake
- Planned surgery or hospitalization during the study (scheduled outpatient access surgery allowed)
- Any other medical condition that renders the patient unable to or unlikely to complete the study or that would interfere with optimal participation in the study or produce significant risk to the patient
- Receipt of any investigational drug within 30 days of randomization
- Inability to cooperate with study personnel or history of noncompliance
- Prior exposure to ferric citrate
- Patients with hemochromatosis or Thalassemia
Study Plan
How is the study designed?
Design Details
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
KRX-0502 (ferric citrate)
KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate. All patients initiated on study drug will start with a fixed dose of KRX-0502 (ferric citrate) of 6 caplets per day. Patients will be titrated at Visits 4, 5, and 6 based on serum phosphorus lab results. If serum phosphorus levels go below normal, there will be a decrease in pills; if serum phosphorus levels go above normal, there wil be an increase in pills. The maximum number of KRX-0502 (ferric citrate) caplets per day will be 12, or 12 g/day of ferric citrate. Patients will take study drug orally with meals or snacks or within one hour after their meals or snacks. |
KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Primary Outcome of This Trial Will be the Change in Serum Phosphorus From Baseline to End of Treatment After a Four Week Treatment Period.
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Incidence of Treatment-emergent Adverse Events (New or Worsened From Study Drug Initiation) Will be Summarized by Body System, Severity, Type of Adverse Event, and Presumed Relationship to the Study Drug.
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Itamar Raz, MD, Hadassah University Hospital-Ein Kerem
Publications and helpful links
General Publications
- Hsu CH, Patel SR, Young EW. New phosphate binding agents: ferric compounds. J Am Soc Nephrol. 1999 Jun;10(6):1274-80. doi: 10.1681/ASN.V1061274.
- Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH. An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate. Nephrol Dial Transplant. 2002 Feb;17(2):265-70. doi: 10.1093/ndt/17.2.265.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KRX-0502-202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperphosphatemia
-
Taisho Pharmaceutical Co., Ltd.CompletedHyperphosphatemia Patients on HemodialysisJapan
-
Kissei Pharmaceutical Co., Ltd.CompletedHemodialysis Patients With HyperphosphatemiaJapan
-
Kyowa Kirin Korea Co., Ltd.RecruitingHyperphosphatemiaKorea, Republic of
-
Kyowa Kirin Co., Ltd.CompletedHyperphosphatemiaJapan
-
Kyowa Kirin Co., Ltd.CompletedHyperphosphatemiaJapan
-
BayerCompleted
-
Washington University School of MedicineCompletedHyperphosphatemiaUnited States
-
Fresenius Medical Care North AmericaRenal Research InstituteCompleted
-
BayerCompletedHyperphosphatemia | DialysisJapan
Clinical Trials on ferric citrate
-
Sreedhar MandayamKeryx BiopharmaceuticalsActive, not recruitingChronic Kidney Diseases | End Stage Renal DiseaseUnited States
-
Keryx BiopharmaceuticalsCollaborative Study Group (CSG)CompletedEnd-Stage Renal Disease | HyperphosphatemiaUnited States, Puerto Rico
-
Kaiser PermanenteKeryx BiopharmaceuticalsCompletedHyperphosphatemiaUnited States
-
Keryx BiopharmaceuticalsCollaborative Study Group (CSG)CompletedHyperphosphatemia | End-stage Renal DiseaseUnited States
-
Keryx BiopharmaceuticalsRecruitingHyperphosphatemia Related to Chronic Kidney DiseaseUnited States
-
Denver Nephrologists, P.C.Keryx BiopharmaceuticalsCompletedRenal Insufficiency | Chronic Kidney Disease | Iron Deficiency Anemia | HyperphosphatemiaUnited States
-
Keryx BiopharmaceuticalsCompletedChronic Kidney Diseases | Iron Deficiency AnemiaUnited States
-
University of California, Los AngelesNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingChronic Kidney DiseasesUnited States, Canada
-
Keryx BiopharmaceuticalsCompletedAnemia of Chronic Kidney DiseaseIsrael
-
Keryx BiopharmaceuticalsCompletedRenal Failure | End Stage Renal Disease | ESRD | Kidney Failure | HyperphosphatemiaUnited States, Puerto Rico